Elucid Secures $55M to Revolutionize Heart Diagnostics with AI
September 9, 2026, 9:33 pm
Location: United States, California, Menlo Park
Employees: 11-50
Founded date: 2020
Elucid, a Boston-based medtech innovator, just secured $55M in an oversubscribed Series D funding. Total capital now reaches $185M. The company pioneers AI-powered software for precision cardiovascular diagnosis and treatment. Funds will accelerate commercial growth for its FDA-cleared Plaque-IQ and BioIntegrated FFR-CT, currently under FDA review. This substantial investment underscores growing industry belief in AI's power to personalize heart care. Elucid's platform provides deep insights into plaque biology and vessel anatomy. It moves beyond generic risk assessments. The goal is individualized patient management for critical heart conditions. This marks a pivotal step in combating global cardiovascular disease.
Elucid strengthens its position in medical technology. The company focuses acutely on cardiovascular health. It announced a $55 million Series D funding round. This round was significantly oversubscribed. It signals robust investor confidence. Total funding for Elucid now approaches $185 million. This capital inflow positions Elucid for substantial growth in AI diagnostics.
The investment attracted powerful new partners. A large medtech company joined as a strategic investor. This entity is publicly traded. It represents Elucid's fourth such strategic partner. This alliance provides significant industry backing. IAG Capital Partners also participated. Elevage Medical Technologies contributed. Elevage operates under Patient Square Capital. This diverse investor base highlights broad industry belief in Elucid’s innovative vision for precision diagnosis.
The new capital fuels ambitious initiatives. Elucid plans to accelerate commercial expansion. This includes its comprehensive clinical platform. The company will significantly boost AI research and development. Advancing pioneering clinical studies remains a critical priority. Landmark trials are already underway. These efforts drive the future of personalized heart care.
Cardiovascular disease remains a leading global killer. Current diagnostic methods often lack precision. Elucid’s medical technology offers a transformative solution. It employs advanced artificial intelligence. This sophisticated software analyzes routine coronary CT angiography scans. It uncovers previously unseen features of cardiovascular risk. The platform uniquely integrates plaque biology, vessel anatomy, and FFR physiology. This provides physicians with profoundly comprehensive patient profiles. It moves beyond general risk factors for heart disease.
Plaque-IQ stands as a flagship product. It holds crucial FDA clearance. This image analysis software precisely quantifies plaque composition. It accurately identifies dangerous plaque in both coronary and carotid arteries. Plaque-IQ helps stratify high-risk patients. Its validation against histopathology is unparalleled. No other non-invasive method currently shares this capability. Physicians gain critical, actionable insights. They can personalize treatment based on actual, individual disease. This represents a significant shift from population-based risk assessments.
Another vital product is BioIntegrated FFR-CT. This advanced tool precisely identifies coronary blockages. It also assesses the full extent of a patient's ischemia non-invasively. FFR-CT is currently under active FDA 510(k) review. Its innovative development builds directly on Elucid’s existing sophisticated plaque algorithm. It seamlessly integrates anatomy, plaque biology, and physiology. This aims for highly consistent, profoundly personalized cardiovascular assessment across diverse patient populations.
Elucid is actively integrating these powerful diagnostic tools. A new, intuitive user interface is under active development. This will seamlessly combine the capabilities of Plaque-IQ and BioIntegrated FFR-CT. The strategic goal is a complete, unified clinical decision system. This system will precisely quantify a subject’s overall cardiovascular risk. Physicians will gain unprecedented clarity. They will make more informed, data-driven treatment choices. Patient outcomes could improve dramatically. This integration represents a major leap forward in diagnostic capability for atherosclerosis.
Atherosclerotic cardiovascular disease poses an immense global health challenge. Elucid targets this burden directly and innovatively. Its non-invasive imaging technology offers a new paradigm for early detection and personalized management. The company’s approach champions truly personalized coronary artery disease management. It empowers clinicians to identify subtle disease features that traditional assessments often overlook. This precision allows for earlier, more targeted interventions.
CEO Kelly Huang leads Elucid’s strategic direction. The company’s core strategy is unequivocal. It combines rigorous clinical validation with cutting-edge AI research. This positions its comprehensive platform for widespread adoption across cardiology. The technology helps move medicine beyond broad, population-based risk models. It sharply focuses on individual disease characteristics. This supports more precise prevention strategies and tailored treatment decisions. Elucid is building the future of heart care.
The latest financing provides crucial operational resources. Elucid will aggressively expand its clinical platform's reach. Regulatory progress provides a strong foundation for this growth. The investment also strategically strengthens its network of critical medtech partners. This robust backing reflects increasing industry confidence in AI-powered cardiovascular diagnostics. The market recognizes the transformative potential of Elucid's technology.
Elucid envisions a future of truly precise cardiac care. The next major milestone involves FDA clearance for BioIntegrated FFR-CT. Commercial expansion will rapidly follow this pivotal regulatory approval. The company remains committed to continuously advancing the field. It relentlessly innovates in novel AI R&D. Elucid is redefining the global fight against heart disease. Its integrated technology offers tangible hope for millions. Precision medicine in cardiology is no longer a theoretical concept. Elucid actively makes it a clinical reality.
Elucid strengthens its position in medical technology. The company focuses acutely on cardiovascular health. It announced a $55 million Series D funding round. This round was significantly oversubscribed. It signals robust investor confidence. Total funding for Elucid now approaches $185 million. This capital inflow positions Elucid for substantial growth in AI diagnostics.
The investment attracted powerful new partners. A large medtech company joined as a strategic investor. This entity is publicly traded. It represents Elucid's fourth such strategic partner. This alliance provides significant industry backing. IAG Capital Partners also participated. Elevage Medical Technologies contributed. Elevage operates under Patient Square Capital. This diverse investor base highlights broad industry belief in Elucid’s innovative vision for precision diagnosis.
The new capital fuels ambitious initiatives. Elucid plans to accelerate commercial expansion. This includes its comprehensive clinical platform. The company will significantly boost AI research and development. Advancing pioneering clinical studies remains a critical priority. Landmark trials are already underway. These efforts drive the future of personalized heart care.
Cardiovascular disease remains a leading global killer. Current diagnostic methods often lack precision. Elucid’s medical technology offers a transformative solution. It employs advanced artificial intelligence. This sophisticated software analyzes routine coronary CT angiography scans. It uncovers previously unseen features of cardiovascular risk. The platform uniquely integrates plaque biology, vessel anatomy, and FFR physiology. This provides physicians with profoundly comprehensive patient profiles. It moves beyond general risk factors for heart disease.
Plaque-IQ stands as a flagship product. It holds crucial FDA clearance. This image analysis software precisely quantifies plaque composition. It accurately identifies dangerous plaque in both coronary and carotid arteries. Plaque-IQ helps stratify high-risk patients. Its validation against histopathology is unparalleled. No other non-invasive method currently shares this capability. Physicians gain critical, actionable insights. They can personalize treatment based on actual, individual disease. This represents a significant shift from population-based risk assessments.
Another vital product is BioIntegrated FFR-CT. This advanced tool precisely identifies coronary blockages. It also assesses the full extent of a patient's ischemia non-invasively. FFR-CT is currently under active FDA 510(k) review. Its innovative development builds directly on Elucid’s existing sophisticated plaque algorithm. It seamlessly integrates anatomy, plaque biology, and physiology. This aims for highly consistent, profoundly personalized cardiovascular assessment across diverse patient populations.
Elucid is actively integrating these powerful diagnostic tools. A new, intuitive user interface is under active development. This will seamlessly combine the capabilities of Plaque-IQ and BioIntegrated FFR-CT. The strategic goal is a complete, unified clinical decision system. This system will precisely quantify a subject’s overall cardiovascular risk. Physicians will gain unprecedented clarity. They will make more informed, data-driven treatment choices. Patient outcomes could improve dramatically. This integration represents a major leap forward in diagnostic capability for atherosclerosis.
Atherosclerotic cardiovascular disease poses an immense global health challenge. Elucid targets this burden directly and innovatively. Its non-invasive imaging technology offers a new paradigm for early detection and personalized management. The company’s approach champions truly personalized coronary artery disease management. It empowers clinicians to identify subtle disease features that traditional assessments often overlook. This precision allows for earlier, more targeted interventions.
CEO Kelly Huang leads Elucid’s strategic direction. The company’s core strategy is unequivocal. It combines rigorous clinical validation with cutting-edge AI research. This positions its comprehensive platform for widespread adoption across cardiology. The technology helps move medicine beyond broad, population-based risk models. It sharply focuses on individual disease characteristics. This supports more precise prevention strategies and tailored treatment decisions. Elucid is building the future of heart care.
The latest financing provides crucial operational resources. Elucid will aggressively expand its clinical platform's reach. Regulatory progress provides a strong foundation for this growth. The investment also strategically strengthens its network of critical medtech partners. This robust backing reflects increasing industry confidence in AI-powered cardiovascular diagnostics. The market recognizes the transformative potential of Elucid's technology.
Elucid envisions a future of truly precise cardiac care. The next major milestone involves FDA clearance for BioIntegrated FFR-CT. Commercial expansion will rapidly follow this pivotal regulatory approval. The company remains committed to continuously advancing the field. It relentlessly innovates in novel AI R&D. Elucid is redefining the global fight against heart disease. Its integrated technology offers tangible hope for millions. Precision medicine in cardiology is no longer a theoretical concept. Elucid actively makes it a clinical reality.